Evidence map›Paper›PMID 24807715›Full record

ArticleJournal of virology2014

Replication of many human viruses is refractory to inhibition by endogenous cellular microRNAs.

Hal P Bogerd, Rebecca L Skalsky, Edward M Kennedy, Yuki Furuse, Adam W Whisnant, Omar Flores, Kimberly L W Schultz, Nicole Putnam, Nicholas J Barrows, Barbara Sherry and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Hal P BogerdDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Rebecca L SkalskyDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Edward M KennedyDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Yuki FuruseDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Adam W WhisnantDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Omar FloresDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Kimberly L W SchultzW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Nicole PutnamW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Nicholas J BarrowsDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Barbara SherryDepartment of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Frank ScholleDepartment of Biological Sciences, North Carolina State University, Raleigh, North Carolina, USA.
Mariano A Garcia-BlancoDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA.
Diane E GriffinW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Bryan R CullenDepartment of Molecular Genetics & Microbiology, Duke University Medical Center, Durham, North Carolina, USA bryan.cullen@duke.edu.
Duke University Hospital · USDuke Medical Center · USJohns Hopkins University · USNorth Carolina State University · USDuke University · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Yessinia autotransporters (Yaps): Structure, function, and host responseU54AI057157 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SEMPOWSKI, GREGORY D · 2003 to 2013
$91.4M
ORGANIZATION AND FUNCTIONS OF CELLULAR STRUCTUREST32GM007184 · NIGMS · DUKE UNIVERSITY · PI JINKS-ROBERTSON, SUE · 1985 to 2019
$18.2M
CELLULAR &MOLECULAR MECH OF INFLAMMATORY REACTIONST32AI007247 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Joel L Pomerantz · 1985 to 2026
$10.2M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
CONTROL OF ALPHAVIRUS REPLICATION IN THE NERVOUS SYSTEMR01NS038932 · NINDS · JOHNS HOPKINS UNIVERSITY · PI GRIFFIN, DIANE E · 2001 to 2016
$4.9M
Discovery and development of broad spectrum anti-flaviviral drugsR01AI089526 · NIAID · DUKE UNIVERSITY · PI ENGEL, DANIEL A, GARCIA-BLANCO, MARIANO A. · 2010 to 2014
$4.1M
Reovirus Modulation of the Cardiac Innate Response: Type I Interferon and HSP25R01AI083333 · NIAID · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI SHERRY, BARBARA · 2011 to 2015
$1.9M
HIV-1: microRNA interactionsR01DA030086 · NIDA · DUKE UNIVERSITY · PI CULLEN, BRYAN R. · 2010 to 2014
$1.9M
NCI NIH HHS P30 CA014236NCI NIH HHS T32 CA009111NCI NIH HHS T32-CA009111NIAID NIH HHS R01 AI083333NIAID NIH HHS R01-AI083333NIAID NIH HHS R01 AI089526NIAID NIH HHS R01-AI089526NIAID NIH HHS R01-AI0973376NIAID NIH HHS T32 AI007247NIAID NIH HHS T32-AI007247NIAID NIH HHS T32 AI007392NIAID NIH HHS T32-AI007392NIAID NIH HHS U54 AI057157NIAID NIH HHS U54-AI057157NIDA NIH HHS R01-DA0300086NIDA NIH HHS R01 DA030086NIGMS NIH HHS T32 GM007184NINDS NIH HHS R01 NS038932NINDS NIH HHS R01-NS038932
6 · The paper itself

Abstract

The issue of whether viruses are subject to restriction by endogenous microRNAs (miRNAs) and/or by virus-induced small interfering RNAs (siRNAs) in infected human somatic cells has been controversial. Here, we address this question in two ways. First, using deep sequencing, we demonstrate that infection of human cells by the RNA virus dengue virus (DENV) or West Nile virus (WNV) does not result in the production of any virus-derived siRNAs or viral miRNAs. Second, to more globally assess the potential of small regulatory RNAs to inhibit virus replication, we used gene editing to derive human cell lines that lack a functional Dicer enzyme and that therefore are unable to produce miRNAs or siRNAs. Infection of these cells with a wide range of viruses, including DENV, WNV, yellow fever virus, Sindbis virus, Venezuelan equine encephalitis virus, measles virus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus type 1, or herpes simplex virus 1 (HSV-1), failed to reveal any enhancement in the replication of any of these viruses, although HSV-1, which encodes at least eight Dicer-dependent viral miRNAs, did replicate somewhat more slowly in the absence of Dicer. We conclude that most, and perhaps all, human viruses have evolved to be resistant to inhibition by endogenous human miRNAs during productive replication and that dependence on a cellular miRNA, as seen with hepatitis C virus, is rare. How viruses have evolved to avoid inhibition by endogenous cellular miRNAs, which are generally highly conserved during metazoan evolution, remains to be determined. Importance: Eukaryotic cells express a wide range of small regulatory RNAs, including miRNAs, that have the potential to inhibit the expression of mRNAs that show sequence complementarity. Indeed, previous work has suggested that endogenous miRNAs have the potential to inhibit viral gene expression and replication. Here, we demonstrate that the replication of a wide range of pathogenic viruses is not enhanced in human cells engineered to be unable to produce miRNAs, indicating that viruses have evolved to be resistant to inhibition by miRNAs. This result is important, as it implies that manipulation of miRNA levels is not likely to prove useful in inhibiting virus replication. It also focuses attention on the question of how viruses have evolved to resist inhibition by miRNAs and whether virus mutants that have lost this resistance might prove useful, for example, in the development of attenuated virus vaccines.

Indexed as

Host-Pathogen InteractionsImmune EvasionVirus ReplicationAnimalsCell LineGene SilencingHumansMicroRNAsVirusesMicroRNAs

Identifiers

PMID24807715
PMCPMC4097787
OpenAlexW2142817594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.